FindTrial
Sign In

Continuous vs intermittent weekly docetaxel in the elderly patient with advanced and hormone-refractory prostate cancer: a randomized phase II study - ND

Continuous vs intermittent weekly docetaxel in the elderly patient with advanced and hormone-refractory prostate cancer: a randomized phase II study - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-001632-13-IT
Enrollment
Unknown
Registered
2009-03-20
Start date
2009-02-24
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced and hormone-refractory prostate cancer MedDRA version: 9.1 Level: LLT Classification code 10036909 Term: Prostate cancer metastatic

Interventions

Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Docetaxel Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Pharmac

Sponsors

LEGA ITALIANA PER LA LOTTA CONTRO I TUMORI
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: - Hormone-refractory prostate cancer in biochemical remission following two cycles of chemotherapy with weekly docetaxel - Age > 70 years - ECOG PS =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Brain metastases - Uncontrolled infections - Heart failure or ischemic heart disease

Design outcomes

Primary

MeasureTime frame
Main Objective: To compare the quality of life in two arms;Secondary Objective: To compare the overall survival To compare the toxicity To compare the saving in drug costs;Primary end point(s): See main objective—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026